Gastrointestinal motility modulating drugs include all compounds which have pharmacological

MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES

Enrique Rey Professor of Medicine Head. Department of Digestive Diseases Hospital Clínico San Carlos Complutense University Madrid, Spain MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES CONSTIPATION:

Number of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI

Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review

DOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the

DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.

The Opportunity: c-ibs and pain relief with confidence YKP10811

The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors

Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments

Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology

Effect of Itopride Hydrochloride on the Ileal and Colonic Motility in Guinea Pig In Vitro

Yonsei Med J 49(3):472-478, 2008 DOI 10.3349/ymj.2008.49.3.472 Effect of Itopride Hydrochloride on the Ileal and Colonic Motility in Guinea Pig In Vitro Hyun Chul Lim, 1 Young Gyun Kim, 1 Jung Hyun Lim,

Gastroparesis. - Recent advances in the pathophysiology and treatment -

ICDM 2015 Gastroparesis - Recent advances in the pathophysiology and treatment - Department of Internal Medicine, College of Medicine, St. Paul s hospital, The Catholic University of Korea, Seoul, Korea

PRUCAPLA Tablets (Prucalopride)

Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium

pissn: eissn: Journal of Neurogastroenterology and Motility

JNM J Neurogastroenterol Motil, Vol. 21 No. 3 July, 2015 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm15094 Review Prokinetics in the Management of Functional Gastrointestinal Disorders

Dr. Patsy Smyth, FNP-BC

Dr. Patsy Smyth, FNP-BC Gastroparesis literally translated means stomach paralysis. Gastroparesis is a syndrome characterized by delayed gastric emptying in absence of mechanical obstruction of the stomach.

Gastroparesis and other upper GI problems DR ANDREW DAVIES

Gastroparesis and other upper GI problems DR ANDREW DAVIES Outline Gastroparesis Hiccoughs Gastroparesis Gastroparesis Definition: A syndrome of objectively delayed gastric emptying in the absence of mechanical

Emerging Treatments for IBS-C and Clinical Trial Endpoints

Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort

GASTROPARESIS. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis

GASTROPARESIS C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Symptom Definitions Nausea: a subjective feeling of wanting to vomit Vomiting: forceful expulsion of gastroduodenal

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR:

Core Safety Profile Active substance: Rizatriptan Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg P RMS: NL/H/PSUR/0002/001 Date of FAR: 23.05.2011 4.3 Contraindications

JNM Journal of Neurogastroenterology and Motility

JNM Journal of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol. 20 No. 4 October, 2014 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm14010 Original Article Effects of

Pathophysiology/Etiology As with most diseases in the veterinary

VETTALK Volume 15, Number 04 American College of Veterinary Pharmacists THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE IN PETS Introduction The moving topic of this Vet Talk newsletter will be prokinetic

The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders

GASTROENTEROLOGY 2007;132:397 414 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders MICHAEL D. GERSHON*

Management of Gastroparesis

Management of Gastroparesis Bible Class Jan Hendrik Niess As published in Am J Gastroenterol. 2013 Jan;108(1):18-37 What is the definition of gastroparesis? What are cardinal symptoms of gastroparesis?

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol

Vomiting Approach to diagnosis

Vomiting Approach to diagnosis By Dr. Sahar El-Gharabawy Associate professor of internal medicine Hepato-gastroenterology Unit )SMH ) Mansoura University Definitions: Nausea: Feeling "sick to the stomach",

ICCR rotation February 7, The efficacy, safety and tolerability of tegaserod in celiac disease patients

The efficacy, safety and tolerability of tegaserod in celiac disease patients A. Study Purpose and Rationale: Celiac disease is an autoimmune inflammatory disease of the small intestine induced by the

The influence of early postoperative enteral feeding and promotility drugs on upper GI tract and gallbladder motility in the critical care setting

The influence of early postoperative enteral feeding and promotility drugs on upper GI tract and gallbladder motility in the critical care setting Alan Šustić, MD, PhD Dept. of Anesthesiology and ICU Univ.

Propulsion and mixing of food in the alimentary tract Chapter 63

Propulsion and mixing of food in the alimentary tract Chapter 63 Types of GI movements: Propulsive movement-peristalsis Propulsion: controlled movement of ingested foods, liquids, GI secretions, and sloughed

Patient Interview Form

Page 1 of 5 Physicians: D.F. Jackson, III, MD William D. McLaughlin, MD Robert P. Albares, MD Jeffrey J. Crittenden, MD Physicians: Samuel J. Tarwater, MD Travis J. Rutland, MD Ashwani Kapoor, MD Pathologist:

Amyloidosis & the GI Tract

Amyloidosis & the GI Tract John O. Clarke, M.D. Director, Esophageal Program Clinical Associate Professor of Medicine Stanford University john.clarke@stanford.edu 2017 Topics to cover 1) Patterns of GI

Why does my stomach hurt? Exploring irritable bowel syndrome

Why does my stomach hurt? Exploring irritable bowel syndrome By Flavio M. Habal, MD, PhD, FRCPC Case In this article: 1. What is IBS? A 45-year-old female is referred to your office with recurrent 2. How

Buspirone, a new drug for the management of patients with ineffective esophageal motility?

Editorial Buspirone, a new drug for the management of patients with ineffective esophageal motility? United European Gastroenterology Journal 2015, Vol. 3(3) 261 265! Author(s) 2015 Reprints and permissions:

EDUCATION PRACTICE. Management of Delayed Gastric Emptying. Clinical Scenario. The Problem. Management Strategies and Supporting Evidence

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:642 646 EDUCATION PRACTICE Management of Delayed Gastric Emptying FRANK K. FRIEDENBERG and HENRY P. PARKMAN Temple University Hospital, Philadelphia, Pennsylvania

Migraine and Gallbladder Motility

Migraine and Gallbladder Motility Georgescu Doina, MD, PhD Ancusa Oana, MD, PhD Ist Department of Internal Medicine, Victor Babes University of Medicine and Pharmacy, Timisoara Georgescu Liviu-Andrei,

Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director

Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).

Primary Management of Irritable Bowel Syndrome

Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)

ANTI-DEPRESSANT MEDICATIONS

ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

SANDOMIGRAN (pizotifen malate)

SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI

DRUGS THAT ACT IN THE CNS

DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment

Patient Interview Form

Page 1 of 5 Gastroenterologists: D.F. Jackson, III, MD William D. McLaughlin, MD Robert P. Albares, MD Jeffrey J. Crittenden, MD Samuel J. Tarwater, MD Travis J. Rutland, MD Gastroenterologists: Marc L.

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:

M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated

IBS Irritable Bowel syndrome Therapeutics II PHCL 430

Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent

IBS current status Peter Laszlo Lakatos

IBS current status Peter Laszlo Lakatos Semmelweis University 1st Department of Medicine Functional gastrointestinal disorders Chronic or fluctuating functional gastrointestinal symptoms that can not be

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off

Diagnosis and Treatment of Irritable Bowel Syndrome

Special Issue Diagnosis and Treatment of Irritable Bowel Syndrome Myung Gyu Choi, M.D. Department of Internal Medicine The Catholic University of Korea, College of Medicine Kangnam St. Mary's Hospital

Approach to Nausea & Vomi2ng

Approach to Nausea & Vomi2ng Med 3 Seminar 2017 Dr. Robin Grant Division of Pallia2ve Medicine robin.grant@nshealth.ca Why nausea and vomi2ng? Pain 80-90+ % Fa2gue / asthenia 75-90% Cons2pa2on 70% Dyspnea

Use of Prokinetic Agents in Intensive Care Medicine - What is Evidence Based? Dr Martin Sterba PhD EDIC CICM TWH ICU, NSW, Australia

Use of Prokinetic Agents in Intensive Care Medicine - What is Evidence Based? Dr Martin Sterba PhD EDIC CICM TWH ICU, NSW, Australia Ostrava Ostrava Wollongong Wollongong Wollongong Prokinetics and EBM

This initial discovery led to the creation of two classes of first generation antidepressants:

Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out

STRATEGIES TO IMPROVE ENTERAL FEEDING TOLERANCE. IS IT WORTH IT? ENGELA FRANCIS RD(SA)

STRATEGIES TO IMPROVE ENTERAL FEEDING TOLERANCE. IS IT WORTH IT? ENGELA FRANCIS RD(SA) DEFINITION OF ENTERAL FEEDING INTOLERANCE Gastrointestinal feeding intolerance are usually defined as: High gastric

Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders

DRUG PROFILE Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders Anurag Agrawal & Peter Whorwell Author for correspondence ERC Building, First Floor, Wythenshawe

Nausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA

Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea

Nausea and Vomiting in Palliative Care

Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction

Constipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment

CONSTIPATION Constipation An Overview Definition Physiology of GI tract Etiology Assessment Treatment Definition Constipation = the infrequent passage of hard feces Definition of Infrequent The meaning

PRAMIN PRODUCT INFORMATION

PRAMIN PRODUCT INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Pramin Tablets Pramin Injection Pramin Suppositories 5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pramin Tablets: Each tablet contains: Metoclopramide

Coastal Digestive Diseases, P.C. MA New Pt Ht

Coastal Digestive Diseases, P.C. MA New Pt Ht Interview Form Limited Use Only Estab Pt Wt Name Nickname DOB Address Occupation Social Security # Married Single Email Address: Divorced Widowed Check Contact

Mirtazapine in diarrhea-predominant irritable bowel syndrome: an openlabel

Research Article http://www.alliedacademies.org/gastroenterology-and-digestive-diseases/ Mirtazapine in diarrhea-predominant irritable bowel syndrome: an openlabel study. Sanagapalli S 1,2*, Kim E 1, Zarate-Lopez

Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment

REVIEW KEVIN W. OLDEN, MD Associate Professor of Medicine, Division of Gastroenterology, Mayo Clinic Scottsdale, Scottsdale, Ariz. Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment

Chapter 41. Media Directory. Lower Digestive Tract. Constipation (continued) Constipation

Chapter 41 Drugs for Bowel Disorders and Other Gastrointestinal Conditions Slide 43 Media Directory Tegaserod Animation Upper Saddle River, New Jersey 07458 All rights reserved. Lower Digestive Tract Figure

Patient Interview Form

Page 1 of 5 Patient Interview Form Patient Information First Name: MRN: Last Name: Date Of Birth: Contact Preference Email Telephone call- Work Telephone call - Home Email Please check one as your preferred

Health History Questionaire

Patient DOB: Patient Name: Date: Health History Questionaire Who referred your consultation? If no one referred you, how did you hear about us? Who is your primary care physician? Have you ever seen a

Is one of the most common chronic disorders. causing patients to seek medical treatment.

ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing

Our evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders.

Our evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders. SmartPill benefits your practice: Convenient performed right in your office Test standardization Provides direct

Management of Functional Dyspepsia (FD)

Management of Functional Dyspepsia (FD) Amy S. Oxentenko, MD, FACG Program Director and Associate Chair, IM Associate Professor of Medicine Mayo Clinic, Rochester Outline Define functional dyspepsia (FD)

A SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017

A SLP s Guide to Medication Therapy and Management Sarah Luby, PharmD, BCPS KSHA 2017 Objectives Identify the appropriate route of administration for medications and proper formulations for use Understand

Functional Dyspepsia

Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology

New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome

New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised

CYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis

CYCLIC VOMITING SYNDROME C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Case 26 year old male Symptoms began at age 19 yr 5-6 day episodes of recurrent, severe vomiting

Migraleve, Migraleve Pink and Migraleve Yellow Product Information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also

GI Complications in heds and HSD

GI Complications in heds and HSD Qasim Aziz PhD, FRCP Professor in Neurogastroenterology Neurogastroenterology Group GUT = Gastrointestinal (GI) tract Oesophagus / gullet Gastro-oesophageal junction Stomach

MANAGEMENT OF VISCERAL PAIN

MANAGEMENT OF VISCERAL PAIN William D. Chey, MD, FACG Professor of Medicine University of Michigan 52 year old female with abdominal pain 5 year history of persistent right sided burning/sharp abdominal

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

F A M N O P R S ! D !

A B C D E F A M N O P Q G H I J R S T U V 595 W http://www.encognitive.com/images/digestive-system-2.jpg K L M A N B C O P D E F G D Q R H S I J K http://apbrwww5.apsu.edu/thompsonj/anatomy%20&%20physiology/2020/2020%20exam%20reviews/exam%203/colon%20diagram.jpgd

Treatments for migraine

Treatments for migraine Information for patients and carers Department of Neurology Aberdeen Royal Infirmary Contents Page About this leaflet Abortive medication for migraine Painkillers Antisickness medication

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

Aliment Pharmacol Ther 2005; 22: 381 385. doi: 10.1111/j.1365-2036.2005.02566.x The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine

Index. Note: Page numbers of article titles are in boldface type.

Note: Page numbers of article titles are in boldface type. A Achalasia, barium esophagography for, 57 58 Acid pocket, 18 19 Acid-sensing ion, 20 Acupuncture, 128 Adiponectin, in obesity, 166 ADX10059 metabotropic

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Z Gastroenterol. 1983 Mar;21 Suppl:111-6. [Effect of antacids on intestinal motility]. [Article in German] Wienbeck M, Erckenbrecht J, Strohmeyer G. Abstract

Bend Surgical Associates. Michael J. Mastrangelo, MD, FACS. Medication Name Dosage Frequency Medication Name Dosage Frequency

Bend Surgical Associates Michael J. Mastrangelo, MD, FACS PATIENT NAME: DATE F BIRTH: MEDICATINS Please list all of your current prescription, non-prescription medications, vitamins, minerals, and supplements.

Prevalence of IBS Diagnosis

Irritable Bowel Syndrome: Past, Present, and Future G. Nicholas Verne, M.D. Professor and Division Director Division of Gastroenterology, Hepatology, Nutrition Department of Internal Medicine Ohio State

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 PRODUCT NAME TROPISETRON-AFT tropisetron hydrochloride (equivalent to 2 mg or 5 mg tropisetron) per ampoule. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg of tropisetron 1 2 ml ampoule

Gut involvement in PoTS an overview

Gut involvement in PoTS an overview Qasim Aziz, PhD, FRCP Centre for Neuroscience and Trauma Wingate Institute of Neurogastroenterology Case Hx * 28 year old lady presents with a long hx of constipation

Levocetirizine dihydrochloride

INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. linezolid tablets

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr ZYVOXAM linezolid tablets Read this carefully before you start taking ZYVOXAM and each time you get a refill. This

Gastrointestinal Physiology. Intensive Care Training Program Radboud University Nijmegen Medical Centre

Gastrointestinal Physiology Intensive Care Training Program Radboud University Nijmegen Medical Centre Content Gastrointestinal blood flow Portal hypertension Motility disorders Specific metabolic disorders

AUTOCOIDS. Mr. D.Raju, M.pharm, Lecturer

AUTOCOIDS Mr. D.Raju, M.pharm, Lecturer DEFINITION An organic substance, such as a hormone, produced in one part of organism and transported by the blood or lymph to another part of the organism where

The GI tract in PD: From Beginning to End Lauren Seeberger, MD Associate Professor, Neurology University of Colorado, Denver

The GI tract in PD: From Beginning to End Lauren Seeberger, MD Associate Professor, Neurology University of Colorado, Denver The Problems Introduc

Disorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional

June By: Reza Gholami

ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal

) and serotonin Type 2 (5-HT 2A

Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the

WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?

WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein

Fecal incontinence causes 196 epidemiology 8 treatment 196

Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea

Clinical Trial Results Summary Study EN3409-BUP-305

Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin

Defense Technical Information Center Compilation Part Notice

UNCLASSIFIED Defense Technical Information Center Compilation Part Notice ADPO 11045 TITLE: Gastrointestinal Drugs in Aircrew DISTRIBUTION: Approved for public release, distribution unlimited This paper

SUMMARY OF PRODUCT CHARACTERISTICS

MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.

When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity

When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After

Antidepressant Pharmacology An Overview

Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited

La tasca acida nella MRGE: aspetti patogenetici e terapeutici

La tasca acida nella MRGE: aspetti patogenetici e terapeutici Prof. VINCENZO SAVARINO Professore Ordinario di Gastroenterologia, Università degli Studi di Genova Direttore della Clinica Gastroenterologica

Disclosures. Objectives. Gastroparesis: Are We Moving On? Gastroparesis: Clinical Overview

Gastroparesis: Are We Moving On? Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Beth Israel Deaconess Medical Center Boston, MA Disclosures Consultant Alkermes, Allergan, Forest,

David Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:

David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical